DDInter1420 DDInter1376
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pentamidine {u} (Compound) resembles {v} (Compound) Ospemifene
Pentamidine {u} (Compound) binds {v} (Gene) S100B
Pentamidine {u} (Compound) upregulates {v} (Gene) CDK7
Pentamidine {u} (Compound) downregulates {v} (Gene) TYMS
Pentamidine {u} (Compound) causes {v} (Side Effect) Azotaemia
Pentamidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Galantamine
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Pentamidine (Compound) resembles Ospemifene (Compound)
Pentamidine (Compound) binds S100B (Gene)
Pentamidine (Compound) upregulates CDK7 (Gene)
Pentamidine (Compound) downregulates TYMS (Gene)
Pentamidine (Compound) causes Azotaemia (Side Effect)
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Galantamine
Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Pentamidine may lead to a major life threatening interaction when taken with Bexarotene